1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Alzheimer Disease

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Alzheimer Disease in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (12.50)	18.2507
2000's	2 (25.00)	29.6817
2010's	5 (62.50)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Berger, J; Dorninger, F; Fischer, P; Forss-Petter, S; Gleiss, A; Hinterberger, M; Jungwirth, S; Kou, J; Moser, AB; Wiesinger, C	1
Shi, C; Wu, F; Xu, J	1
Ahmed, F; Baetz, K; Bennett, SA; Bryan, J; Figeys, D; Kabbani, N; Kennedy, MA; Lambert, JP; Swayne, LA	1
Farooqui, AA; Farooqui, T; Frisardi, V; Panza, F; Seripa, D	1
Broccatelli, F; Budriesi, R; Carosati, E; Chiarini, A; Cruciani, G; Ioan, P; Micucci, M; Zhorov, BS	1
Choi, HB; Kim, SU; Lue, LF; McLarnon, JG; Walker, DG	1
Chen, HZ; Dong, CZ; Ezoulin, MJ; Heymans, F; Li, J; Massicot, F; Ombetta, JE; Wu, G	1
Lithner, F	1

Reviews

2 review(s) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Alzheimer Disease

Article	Year
Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer's disease pathology. Progress in lipid research, 2011, Volume: 50, Issue:4 Topics: Aldehydes; Alzheimer Disease; Arachidonic Acids; Brain; Cannabinoids; Dietary Fats; Docosahexaenoic Acids; Fatty Acids, Unsaturated; Glycerophospholipids; Humans; Lipid Metabolism; Lysophospholipids; Oxidation-Reduction; Phospholipases A2; Platelet Activating Factor; Reactive Oxygen Species	2011
1,4-Dihydropyridine scaffold in medicinal chemistry, the story so far and perspectives (part 2): action in other targets and antitargets. Current medicinal chemistry, 2012, Volume: 19, Issue:25 Topics: Alzheimer Disease; Animals; Antitubercular Agents; Atherosclerosis; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dihydropyridines; Drug Resistance, Multiple; Humans; Platelet Activating Factor; Tuberculosis	2012

Article

Year

Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer's disease pathology.

Progress in lipid research, 2011, Volume: 50, Issue:4

Topics: Aldehydes; Alzheimer Disease; Arachidonic Acids; Brain; Cannabinoids; Dietary Fats; Docosahexaenoic Acids; Fatty Acids, Unsaturated; Glycerophospholipids; Humans; Lipid Metabolism; Lysophospholipids; Oxidation-Reduction; Phospholipases A2; Platelet Activating Factor; Reactive Oxygen Species

2011

1,4-Dihydropyridine scaffold in medicinal chemistry, the story so far and perspectives (part 2): action in other targets and antitargets.

Current medicinal chemistry, 2012, Volume: 19, Issue:25

Topics: Alzheimer Disease; Animals; Antitubercular Agents; Atherosclerosis; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dihydropyridines; Drug Resistance, Multiple; Humans; Platelet Activating Factor; Tuberculosis

2012

Other Studies

6 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Alzheimer Disease

Article	Year
Alterations in the Plasma Levels of Specific Choline Phospholipids in Alzheimer's Disease Mimic Accelerated Aging. Journal of Alzheimer's disease : JAD, 2018, Volume: 62, Issue:2 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Biomarkers; Female; Humans; Logistic Models; Longitudinal Studies; Lysophosphatidylcholines; Male; Mass Spectrometry; Plasmalogens; Platelet Activating Factor	2018
H2O2 and PAF mediate Abeta1-42-induced Ca2+ dyshomeostasis that is blocked by EGb761. Neurochemistry international, 2010, Volume: 56, Issue:8 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Calcium; Calcium Signaling; Cells, Cultured; Ginkgo biloba; Glutamic Acid; Hippocampus; Homeostasis; Hydrogen Peroxide; Neurons; Oxidative Stress; Peptide Fragments; Plant Extracts; Platelet Activating Factor; Rats; Rats, Sprague-Dawley	2010
Srf1 is a novel regulator of phospholipase D activity and is essential to buffer the toxic effects of C16:0 platelet activating factor. PLoS genetics, 2011, Feb-10, Volume: 7, Issue:2 Topics: Alzheimer Disease; Cell Line; Glycerophospholipids; Humans; Lipid Metabolism; Mutation; Neurons; Phospholipase D; Platelet Activating Factor; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins	2011
Perturbations in calcium-mediated signal transduction in microglia from Alzheimer's disease patients. Journal of neuroscience research, 2005, Aug-01, Volume: 81, Issue:3 Topics: Adenosine Triphosphate; Alzheimer Disease; Amyloid beta-Peptides; Analysis of Variance; Calcium; Cells, Cultured; Drug Interactions; Fetus; Humans; Microglia; Peptide Fragments; Platelet Activating Factor; Postmortem Changes; Signal Transduction; Spectrometry, Fluorescence	2005
Differential effect of PMS777, a new type of acetylcholinesterase inhibitor, and galanthamine on oxidative injury induced in human neuroblastoma SK-N-SH cells. Neuroscience letters, 2005, Dec-02, Volume: 389, Issue:2 Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Encephalitis; Furans; Galantamine; Glutathione; Humans; Inflammation Mediators; Interleukin-1; Lipopolysaccharides; Mitochondria; Neuroblastoma; Neurons; Neuroprotective Agents; Oxidative Stress; Platelet Activating Factor; Reactive Oxygen Species	2005
Diabetes mellitus and Alzheimer's disease. Diabetologia, 1996, Volume: 39, Issue:10 Topics: Aged; Alzheimer Disease; Cerebrovascular Disorders; Confusion; Dementia, Multi-Infarct; Diabetes Complications; Diabetes Mellitus; Glucose Tolerance Test; Humans; Incidence; Insulin; Platelet Activating Factor; Reference Values; Sweden	1996